{"id":27892,"date":"2025-02-04T15:45:00","date_gmt":"2025-02-04T14:45:00","guid":{"rendered":"https:\/\/qlinea.com\/mfn_news\/ghent-university-publishes-astar-study-results\/"},"modified":"2025-02-04T21:27:30","modified_gmt":"2025-02-04T20:27:30","slug":"ghent-university-publishes-astar-study-results","status":"publish","type":"mfn_news","link":"https:\/\/qlinea.com\/us\/mfn_news\/ghent-university-publishes-astar-study-results\/","title":{"rendered":"Ghent University publishes ASTar study results"},"content":{"rendered":"
\n

Q-linea AB (publ) (OMX:QLINEA) today announces that results from a Belgian study have been published in the European Journal of Clinical Microbiology & Infectious Diseases.<\/strong><\/p>\n<\/div>\n

\n

A group from Ghent University conducting an interventional study recently published two articles showing clinical benefits of ASTar System for patients with bacteremia caused by Gram-negative bacteria. The performance was good and ASTar results were available 17 hours faster than the standard workflow. In 17.6% of patients, the clinicians changed the initial antibiotic therapy within one hour of the ASTar results being available, due to resistance to the initial therapy. ASTar also showed an opportunity for adapting the therapy in 63% of patients and in half of these the therapy was adapted within three hours.<\/p>\n

The second article shows how early detection of bacteria with specific resistance profiles can be facilitated by rapid MIC results from ASTar. Results from the ASTar System were available approximately six hours from positive blood culture from an immunocompromised patient and used in support of changed antimicrobial therapy 16 hours earlier than standard workflow.<\/p>\n<\/div>\n

\n

For more information, please contact:<\/strong><\/p>\n

\n

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com<\/a>
+1 857 409 7463<\/p>\n

Christer Samuelsson, CFO \/IR, Q-linea AB
Christer.Samuelsson@qlinea.com<\/a>
+46 (0) 70-600 15 20<\/p>\n<\/div>\n

\n

About Q-linea<\/strong><\/p>\n

\n

Q-linea’s rapid AST system, ASTar®, accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.
Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.
ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com<\/p>\n<\/div>\n

\n

Attachments<\/strong><\/p>\n

\n

Ghent University publishes ASTar study results<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Q-linea AB (publ) (OMX:QLINEA) today announces that results from a Belgian study have been published in the European Journal of Clinical Microbiology & Infectious Diseases….<\/p>\n","protected":false},"template":"","class_list":["post-27892","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci-us","mfn-news-tag-mfn-lang-en-us","mfn-news-tag-mfn-type-ir-us","mfn-news-tag-mfn-us","mfn-news-tag-mfn-ci-other-us","mfn-news-tag-mfn-ci-other_sv-us"],"acf":[],"_links":{"self":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/mfn_news\/27892","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/qlinea.com\/us\/wp-json\/wp\/v2\/media?parent=27892"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}